Search

Supplementary figures S1-S6, tables 1 and 2. Table S1. Body weight loss and health observations in HeyA8 xenograft tumor-bearing mice treated with PARP inhibitors or TMZ alone or in combination. Table S2. Summary of PK parameters in HeyA8 xenograft tumor-bearing mice. Figure S1. PARP inhibitors potentiate the activity of alkylating agents in vitro. Figure S2. Equilibrium binding of PARP inhibitors to PARP1. Figure S3. Analysis of PARP1-DNA binding kinetics by BLI. Figure S4. Michaelis-Menten analysis of the mode of inhibition of different PARP inhibitors. Figure S5. γH2AX levels by cell cycle phase in HeyA8 cells treated with MMS and PARP inhibitors alone and in combination. Figure S6. Pharmacokinetics and pharmacodynamics in HeyA8 xenograft tumor-bearing mice.

Association of PARP1 and H2A.X detected by Proximity Ligation Assay (PLA).

Association of PARP1 and other histone proteins detected by Proximity Ligation Assay (PLA).

IC50 values of PARPi vs BM-CFU and BM-PAR

Clinical RP2D concentrations for PARP inhibitors.

Bone Marrow IC50s broken into cell type.

Materials that emit circularly polarized light have application in several important industries. Deep eutectic solvents (DES) with chiral components are attractive as solvents of luminescent lanthanides for the development of chiral light-emitting materials. Deep eutectic solvents are prepared with combinations of tetrabutylammonium (or tetrabutylphosphonium) chloride as hydrogen bond acceptor (HBA) and amino acids, l-and d-glutamic acid, l-proline, and l-arginine as hydrogen bond donor (HBD). A racemic mixture of dissymmetric lanthanide (europium, terbium, and samarium) complexes is dissolved in the DES to measure the induced circularly polarized luminescence (CPL). This resulted in green, orange, and red CPL with a sign that is dictated by the enantiomer of the amino acid in the DES. Thermodynamic measurements show that changing the salt from tetrabutylammonium to tetrabutylphosphonium leads to a 50% increase in the enthalpy and entropy of chiral discrimination. This study demonstrates the capability of chiral DES as a solvent for chiral light-emitting materials and the ability to control this capability through the choice of HBA and HBD.

The luminescence properties of Tb 3+ and Eu 3+ dissolved in ionic liquids are studied. Solutes in this study include simple lanthanide compounds (e.g., EuBr 3 , TbCl 3 ) and lanthanide complexes (e.g., Eu(dpa) 3 3− where dpa = 2,6 pyridine dicarboxylate dianion) dissolved in a 1-butyl-3-methylimidazolium bromide(BMIBr)/water mixture. Emission, excitation, and time-resolved emission measurements are utilized to characterize the spectroscopic properties. It is well established in the literature that the solubility and spectroscopic properties of lanthanides in ionic liquids are highly dependent upon environmental factors including purity, and water content [K. Binnemans, Chemical Reviews (2007); I. Billard, S. Mekki, C. Gaillard, P. Hesemann, C. Mariet, G. Moutiers, A. Labet, J.-C.G. Bunzli, European Journal of Inorganic Chemistry 6 (2004) 1190–1197; S. Samikkanu, K. Mellem, M. Berry, P.S. May, Inorganic Chemistry 46 (2007) 7121–7128]. The water in this ionic liquid system acts as a co-solvent to facilitate solubility of Tb 3+ and Eu 3+ compounds. The observed spectroscopic properties of Eu 3+ and Tb 3+ salts are expectedly impacted by the high water content, but unexpectedly impacted by the BMIBr ionic liquid. However, the spectroscopy of Eu(dpa) 3 3− is unaffected by the presence of BMIBr.

Fluorescence from an excited 5f state of Np(VI) has been observed in the doped impurity system Cs{sub 2}U(Np)O{sub 2}Cl{sub 4}. This is the first intra-5f fluorescence transition that has been detected at room temperature in a condensed-phase system with an actinyl (An(VI)O{sub 2}{sup 2+}) core, and it is a rare example of fluorescence of any kind from non-uranyl ions of this type. The emission originates from an excited state approximately 6890cm{sup -1} above the ground state. Its emission spectrum and fluorescence lifetime at 295K will be discussed. Vibronic structure in the emission spectrum is assigned based on comparison with the detailed analysis of the absorption spectra published by Denning et al.

Through broad screening of the compound library at Pharmacia, a naphthalene carboxamide was identified as a nonnucleoside inhibitor of human cytomegalovirus (HCMV) polymerase. Structure-activity relationship studies demonstrated that a quinoline ring could be substituted for naphthalene, resulting in the discovery of a 4-hydroxyquinoline-3-carboxamide (4-HQC) class of antiviral agents with unique biological properties. In vitro assays with the 4-HQCs have demonstrated potent inhibition of HCMV, herpes simplex virus type 1 (HSV-1), and varicella-zoster virus (VZV) polymerases but no inhibition of human α, δ, and γ polymerases. Antiviral cell culture assays have further confirmed that these compounds are active against HCMV, HSV-1, HSV-2, VZV, and many animal herpesviruses. However, these compounds were not active against several nonherpesviruses representing different DNA and RNA virus families. A strong correlation between the viral DNA polymerase and antiviral activity for this class of compounds supports inhibition of the viral polymerase as the mechanism of antiviral activity. Northern blot analysis of immediate-early and late viral transcripts also pointed to a block in the viral life cycle consistent with inhibition of viral DNA replication. In vitro HCMV polymerase assays indicate that the 4-HQCs are competitive inhibitors of nucleoside binding. However, no cross-resistance could be detected with ganciclovir-resistant HCMV or acyclovir-resistant HSV-1 mutants. The unique, broad-spectrum activities of the 4-HQCs may offer new opportunities for treating many of the diseases caused by herpesviruses.

The chiral discrimination ability of amino acid based chiral ionic liquids is studied using chiroptical luminescence techniques. A racemic mixture of dissymmetric europium tris(2,6-pyridinedicarboxylate) complexes are dissolved in five chiral ionic liquids, including l- and d-alanine methyl ester bis(trifluoromethanesulfonimide), l-leucine methyl ester bis(trifluoromethanesulfonimide), l-proline methyl ester bis(trifluoromethanesulfonimide), and tetrabutylammonium l-alanate. Circularly polarized luminescence spectra are measured for the samples over the 283–323 K temperature range. Analysis of the spectroscopic results shows that the amino acid methyl ester chiral ionic liquids show discrimination with a preference (handedness) that corresponds to the stereoisomer (l- vs d-). Most of the chiral ionic liquids show enthalpically dominated discrimination, but l-leucine methyl ester bis(trifluoromethanesulfonimide) shows entropically dominated chiral discrimination.

Emission spectra of NpO2Cl42− doped in a Cs2ZrCl6 matrix have been measured between 6000 and 7200 cm-1. An f-f transition has been assigned, and vibronic structure on this origin is reported. These electronic and vibrational energies are compared with previous studies including the theoretical work of Pitzer and co-workers, and the spectroscopic work of Denning and co-workers.

The 4-oxo-dihydroquinolines (PNU-182171 and PNU-183792) are nonnucleoside inhibitors of herpesvirus polymerases (R. J. Brideau et al., Antiviral Res. 54:19-28, 2002; N. L. Oien et al., Antimicrob. Agents Chemother. 46:724-730, 2002). In cell culture these compounds inhibit herpes simplex virus type 1 (HSV-1), HSV-2, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), and human herpesvirus 8 (HHV-8) replication. HSV-1 and HSV-2 mutants resistant to these drugs were isolated and the resistance mutation was mapped to the DNA polymerase gene. Drug resistance correlated with a point mutation in conserved domain III that resulted in a V823A change in the HSV-1 or the equivalent amino acid in the HSV-2 DNA polymerase. Resistance of HCMV was also found to correlate with amino acid changes in conserved domain III (V823A+V824L). V823 is conserved in the DNA polymerases of six (HSV-1, HSV-2, HCMV, VZV, Epstein-Barr virus, and HHV-8) of the eight human herpesviruses; the HHV-6 and HHV-7 polymerases contain an alanine at this amino acid. In vitro polymerase assays demonstrated that HSV-1, HSV-2, HCMV, VZV, and HHV-8 polymerases were inhibited by PNU-183792, whereas the HHV-6 polymerase was not. Changing this amino acid from valine to alanine in the HSV-1, HCMV, and HHV-8 polymerases alters the polymerase activity so that it is less sensitive to drug inhibition. In contrast, changing the equivalent amino acid in the HHV-6 polymerase from alanine to valine alters polymerase activity so that PNU-183792 inhibits this enzyme. The HSV-1, HSV-2, and HCMV drug-resistant mutants were not altered in their susceptibilities to nucleoside analogs; in fact, some of the mutants were hypersensitive to several of the drugs. These results support a mechanism where PNU-183792 inhibits herpesviruses by interacting with a binding determinant on the viral DNA polymerase that is less important for the binding of nucleoside analogs and deoxynucleoside triphosphates.